CIS-BUTENEDIOIC ACID,2-Morpholinoethanesulfonic acid,N-Ethylcarbazole

Events & Exhibitions Company News Industry News

PEDOT|126213-51-2|—electrochromic material that will go deep into our lives
2017-09-12

Poly(3,4-ethylenedioxythiophene) (PEDOT) is a kind of heterocyclic conductive polymer. Since its first synthesis in the 1990s, its excellent electrochromic properties have become a hotspot in the field of functional materials. In this paper, the principle of electrochromism, the main synthesis methods, and the application of PEDOT are described. Principle of Electrochromism Organic thiophene elect...
Scientists found better transplantation sites for islet
2022-02-15

Researchers from the Westmead Medical Institute in Sydney found better transplantation sites for islet which may lead to more effective treatment of type 1 diabetes. The results of the study have been published under the article entitled "Transplantation sites for human and murine islets" in the international journal "Diabetologia" [1]. According to statistics, there are about 400 million people w...
Type 2 diabetes and coronary heart disease has the same gene?
2017-09-06

Recently, researchers from Perelman Medical School, the University of Pennsylvania, conducted a large number of genetic data analysis, deeply analyzed the pathogenesis of type 2 diabetes, and clarified the relationship between type 2 diabetes and coronary heart disease. The related research results has been published in the international journal Nature Genetics. Diabetes is a group of clinical man...
Preparation of different PEDOT core-shell particles
2017-09-05

Poly(3,4-ethylenedioxythiophene) (PEDOT) are widely used in the field of antistatic coatings, optoelectronic devices, capacitors, electromagnetic shielding, sensors, metal corrosion, etc. due to its high conductivity, low energy gap, excellent film transparency and environmental stability. But its insoluble problem limits its application. In addition to the addition of polystyrene sulfonic acid (P...
New drug in development may make patients with diabetes away from pain!
2017-09-04

Recently, Daiichi Sankyo's official website has published an important outcome of a Phase III clinical trial of its drug Mirogabalin: Mirogabalin has a significant effect in the treatment of diabetic peripheral neuropathy (DPN) and has no major safety concerns. Diabetes is an important public health problem, according to the data from World Health Organization, there are about 400 million people a...
Comparison of Four Synthetic Methods of DPP-4 Inhibitor Saxagliptin
2017-09-01

Saxagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, a drug developed by Bristol-Myers Squibb Pharmaceuticals Inc. for the treatment of adult type II diabetes, which was approved by the FDA in March 2010, and by the SFDA in May 2011. It has the advantages of prominent and lasting efficacy. This paper will summarize and compare the main synthetic routes. Route 1: WO2004052850 [1] 3-hydroxyada...
High hepatic DPP-4 activity can promote NAFLD?
2022-02-15

Researchers from the University of Potsdam and the University of Tübingen have found that high levels of DPP-4 in the liver promote the formation of non-alcoholic fatty liver desease (NAFLD). The study has been published in the journal "Molecular Metabolism". DPP-4 is an enzyme secreted by the liver that decomposes proteins in the body, such as GLP-1. GLP-1 can reduce blood glucose by stimulating ...
Effects of Tris and Bicine Buffers on the In Vitro Properties of ULPs
2017-08-29

Uricase is an important enzyme in the purine metabolic pathway of the organism, which can catalyze the oxygen and uric acid to avoid gout and hyperuricemia caused by excessive accumulation of uric acid in the blood. Urease liposomes (ULPs) overcome the shortcomings of other uricase preparations by packaging drugs in the lipid bilayer, with good stability and high safety, and have a certain functio...
Gocovri was approved by FDA for the treatment of Dyskinesia in Parkinson's Disease
2017-08-28

Recently, Adamas Pharmaceuticals announced in its official website, that Gocovri (amantadine) extended release capsules (previously ADS-5102) for treatment of dyskinesia in patients with Parkinson's disease has been approved by FDA. It is the first and only medicine approved by the FDA for this indication. Parkinson's disease is a chronic neurodegenerative disease that can last for decades. As the...

<< 31 32

34 35 36 37 38 >> a total of

pages